Aditxt, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Aditxt, Inc. (ADTX) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$562.61 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-20.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-05-20
- Aditxt, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$562.61K.
- Aditxt, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$4.01M.
- Aditxt, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $931.66K, a 35.58% decline year-over-year.
- Aditxt, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-06-30 was $3.33M, a 11.93% decline year-over-year.
- Aditxt, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$5.63M, a 210.56% decline from fiscal 2024.
- Aditxt, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $5.10M, a 23.34% decline from fiscal 2023.
- Aditxt, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $6.65M, a 1509.47% increase from fiscal 2022.
- Aditxt, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $412.96K, a 69.04% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-03-31 | -$562.61K 10-Q · filed 2026-05-20 | -$4.58M derived: sum of 2 quarters · filed 2026-05-20 | -$3.64M derived: sum of 3 quarters · filed 2026-05-20 | -$316.06K derived: sum of 4 quarters · filed 2026-05-20 | |
| 2025-12-31 | -$4.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$3.08M derived: sum of 2 quarters · filed 2026-03-31 | $246.55K derived: sum of 3 quarters · filed 2026-03-31 | -$5.63M 10-K · filed 2026-03-31 | |
| 2025-09-30 | $931.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-18 | $4.26M derived: sum of 2 quarters · filed 2025-11-18 | -$1.62M 10-Q · filed 2025-11-18 | -$3.09M derived: sum of 4 quarters · filed 2026-05-20 | |
| 2025-06-30 | $3.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$2.55M 10-Q · filed 2025-08-14 | -$4.03M derived: sum of 3 quarters · filed 2026-05-20 | -$2.58M derived: sum of 4 quarters · filed 2026-05-20 | |
| 2025-03-31 | -$5.88M 10-Q · filed 2026-05-20 | -$7.35M derived: sum of 2 quarters · filed 2026-05-20 | -$5.91M derived: sum of 3 quarters · filed 2026-05-20 | -$2.13M derived: sum of 4 quarters · filed 2026-05-20 | |
| 2024-12-31 | -$1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$27.20K derived: sum of 2 quarters · filed 2026-03-31 | $3.75M derived: sum of 3 quarters · filed 2026-03-31 | $5.10M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $1.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-18 | $5.22M derived: sum of 2 quarters · filed 2025-11-18 | $6.57M 10-Q · filed 2025-11-18 | $10.90M derived: sum of 4 quarters · filed 2025-11-18 | |
| 2024-06-30 | $3.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $5.12M 10-Q · filed 2025-08-14 | $9.45M derived: sum of 3 quarters · filed 2025-08-14 | $8.28M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $1.34M 10-Q · filed 2025-05-15 | $5.67M derived: sum of 2 quarters · filed 2025-05-15 | $4.50M derived: sum of 3 quarters · filed 2025-05-15 | $6.71M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $4.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $3.16M derived: sum of 2 quarters · filed 2025-03-31 | $5.37M derived: sum of 3 quarters · filed 2025-03-31 | $6.65M 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$1.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | $1.04M derived: sum of 2 quarters · filed 2024-11-18 | $2.32M 10-Q · filed 2024-11-18 | $1.59M derived: sum of 4 quarters · filed 2024-11-18 | |
| 2023-06-30 | $2.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-19 | $3.49M 10-Q · filed 2024-08-19 | $2.77M derived: sum of 3 quarters · filed 2024-08-19 | $664.71K derived: sum of 4 quarters · filed 2024-08-19 | |
| 2023-03-31 | $1.28M 10-Q · filed 2024-05-20 | $554.30K derived: sum of 2 quarters · filed 2024-05-20 | -$1.55M derived: sum of 3 quarters · filed 2024-05-20 | $707.17K derived: sum of 4 quarters · filed 2024-05-20 | |
| 2022-12-31 | -$723.49K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | -$2.82M derived: sum of 2 quarters · filed 2024-04-16 | -$570.62K derived: sum of 3 quarters · filed 2024-04-16 | $412.96K 10-K · filed 2024-04-16 | |
| 2022-09-30 | -$2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $152.87K derived: sum of 2 quarters · filed 2023-11-14 | $1.14M 10-Q · filed 2023-11-14 | $1.06M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $3.24M 10-Q · filed 2023-08-14 | $3.16M derived: sum of 3 quarters · filed 2023-08-14 | $3.60M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $983.58K 10-Q · filed 2023-05-15 | $903.15K derived: sum of 2 quarters · filed 2023-05-15 | $1.35M derived: sum of 3 quarters · filed 2023-05-15 | $1.59M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | -$80.43K derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | $363.55K derived: sum of 2 quarters · filed 2023-04-17 | $602.59K derived: sum of 3 quarters · filed 2023-04-17 | $1.33M 10-K · filed 2023-04-17 | |
| 2021-09-30 | $443.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $683.02K derived: sum of 2 quarters · filed 2022-11-14 | $1.41M 10-Q · filed 2022-11-14 | $1.23M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $239.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $970.38K 10-Q · filed 2022-08-15 | $789.40K derived: sum of 3 quarters · filed 2022-08-15 | -$608.23K derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | $731.34K 10-Q · filed 2022-05-16 | $550.35K derived: sum of 2 quarters · filed 2022-05-16 | -$847.27K derived: sum of 3 quarters · filed 2022-05-16 | -$867.26K derived: sum of 4 quarters · filed 2022-05-16 | |
| 2020-12-31 | -$180.99K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$1.58M derived: sum of 2 quarters · filed 2022-03-31 | -$1.60M derived: sum of 3 quarters · filed 2022-03-31 | -$1.48M 10-K · filed 2022-03-31 | |
| 2020-09-30 | -$1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$1.42M derived: sum of 2 quarters · filed 2021-11-15 | -$1.30M 10-Q · filed 2021-11-15 | -$1.30M 10-Q · filed 2020-11-13 | -$1.18M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | -$19.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $95.43K 10-Q · filed 2021-08-12 | $219.85K derived: sum of 3 quarters · filed 2021-08-12 | $331.38K derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $115.42K 10-Q · filed 2021-05-12 | $239.84K derived: sum of 2 quarters · filed 2021-05-12 | $351.37K derived: sum of 3 quarters · filed 2021-05-12 | ||
| 2019-12-31 | $124.42K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $235.95K derived: sum of 2 quarters · filed 2021-03-25 | $601.61K 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $111.53K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $477.19K 10-Q · filed 2020-11-13 | |||
| 2019-06-30 | $365.65K 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |